Ozempic and Semaglutide: New Insights on Weight Loss and Mortality Reduction

Saturday, 31 August 2024, 00:30

Ozempic, a semaglutide drug, shows potential in reducing the risk of death from heart disease and COVID-19 among overweight individuals. The study indicates that participants taking Ozempic were significantly less likely to die from various causes compared to those on placebo during a three-year trial.

Newsweek — Ozempic and Semaglutide: New Insights on Weight Loss and Mortality Reduction

Ozempic's Impact on Mortality

New research delves into how Ozempic, a semaglutide-based medication, may help overweight and obese individuals with heart disease lower their risk of death.

Study Findings

Over 17,500 participants monitored over three years.
19% reduced likelihood of death in semaglutide group.
15% less likely to die from heart issues.
23% reduced likelihood of dying from non-heart-related causes, including COVID-19.

While participants contracted the coronavirus during the trial, those on Ozempic experienced fewer severe consequences.

Mechanism of Action

Semaglutide functions as a GLP-1 analog to suppress appetite and promote weight loss. Despite these findings, the specific reasons for the observed reduction in mortality among users remain unclear.

Broader Implications for Health

This study underscores the potential of semaglutide treatments like Wegovy in managing weight and possibly extending life expectancy for those facing obesity-related health risks.

Final Thoughts

Further investigation is necessary to fully comprehend Ozempic's benefits and the unexpected mortality differences observed.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.